Hugel, a global leader in medical aesthetics, has reported record-breaking financial results for 2025. The company’s consolidated figures show sales of 425.1 billion KRW (about 295 million USD), operating profit of 201.6 billion KRW (about 140 million USD), and net profit of 144 billion KRW (about 99.8 million USD). These numbers represent year-over-year increases of 14%, 21.3%, and 0.6%, respectively, marking the company’s strongest performance to date.
The exceptional 2025 results can be attributed to the strong global market performance of Hugel’s flagship products: the botulinum toxin Botulax (marketed internationally as Letybo), the Hyaluronic Acid (HA) filler The Chaeum (known globally as Revolax), and BYRYZN. Additionally, the company saw rapid growth in its cosmetics lines, WELLAGE and BYRYZNBR.
Breaking down the annual sales, toxins generated 233.8 billion KRW (about 162 million USD) (up 15% year-over-year), fillers brought in 129.7 billion KRW (about 90 million USD) (a 1.7% increase), and cosmetics and other products contributed 61.6 billion KRW (about 42.7 million USD) (surging 45.9%).
The combined annual revenue from Hugel’s key products, toxins and fillers, rose by 10% year-over-year to 363.5 billion KRW (about 252 million USD). Notably, overseas sales in this category reached 268.5 billion KRW (about 186 million USD), marking a significant 22% increase from the previous year. The export share of these two product lines expanded impressively from 66% in 2024 to 74% in 2025.
Geographically, the Americas region, including the United States and Brazil, showed remarkable growth. Combined sales of toxins and fillers in this region more than doubled, reaching 67.9 billion KRW (about 47 million USD) – a 105% year-over-year increase. The region’s fourth-quarter performance was particularly striking, with sales skyrocketing by about 310% year-over-year to 29.2 billion KRW (20.2 million USD).
Hugel is now setting its sights on accelerating its global strategy, with a focus on enhancing both revenue growth and profitability, particularly in the U.S. – the world’s largest market for botulinum toxin products.
Starting this year, the company plans to aggressively expand its market share through a hybrid sales model that combines partner distribution with direct sales, targeting key markets.
Carrie Strom, Hugel’s Global Chief Executive Officer (CEO), commented on the company’s performance: Hugel has achieved a significant milestone by surpassing 400 billion KRW (about 277 million USD) in annual revenue for the first time, showcasing its solid global competitiveness. This year, it aims to further strengthen the long-term global growth foundation, with a strategic focus on its Big Four markets: the U.S., China, Europe, and Brazil.
Hugel’s fourth-quarter results also demonstrated robust growth, with sales reaching 119.1 billion KRW (about 82.5 million USD) (up 21.3% year-over-year) and operating profit hitting 58.6 billion KRW (about 40.6million USD) (a 26.2% increase), underscoring the company’s strong momentum on a quarterly basis.